Faculty Positions

Research Interests

Dr. Kimmel’s research focuses on improving the use of existing therapeutics.  Examples include clinical trials of medication adherence interventions and pharmacogenetics. He is the founding Director of the Center for Therapeutic Effectiveness at Penn.

Selected Publications

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to Rofecoxib and Celecoxib have different odds of nonfatal myocardial infarction.  Ann Intern Med. 2005;142:157-164.

Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R: The influence of patient adherence on anticoagulation control with Warfarin. Arch Intern Med. 2007;167:229-235.

Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS: Apolipoprotein E (APOE) genotype and Warfarin dosing among Caucasians and African Americans. The Pharmacogenomics Journal. 2008;8:53-60.

Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE: Dosing algorithms to predict Warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. 2008;84:332-339.

Kimmel SE, French B, Kasner S, Johnson JA, Anderson JL, Gage BF, et al: A pharmacogenetic versus a clinical algorithm for Warfarin dosing.  NEJM.  2013;369(24):2283-2293.

Recent News